CloneID: Myc123 (Efungumab; Mycograb)
Antigen Long Description: The original antibody was recombinantly generated from the anti-HSP90 antibody cDNA isolated from blood lymphocytes of patients recently recovered from invasive candidiasis.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P46598
Specificity Statement: This antibody binds an epitope comprising amino acid sequence 'NKILKVIRKNIVKK' of heat shock protein 90 of Candida albicans. Homologous epitope have been identified in a number of fungal species like Candida parapsilosis, Torulopsis glabrata, Candida tropicalis, Candida krusei, and Aspergillus fumigatus. Hsp90 is a highly abundant and ubiquitous molecular chaperone which facilitates the maturation, structural maintenance and proper regulation of specific target proteins involved in cellular processes including cell cycle control, cell survival, hormone and other signaling pathways. It is important for the cell's response to stress and is a key player in maintaining cellular homeostasis. In recent years, hsp90 is being considered as an important therapeutic target for cancer and neurodegenerative diseases.
Application Notes (Clone): This anti-fungal antibody has been used for the antibody based therapeutic treatment of systemic and invasive candidiasis (PMID: 11566001; 15040939). In an in vitro assays for efficacy assessment this antibody showed activity against a wide range of yeast species like Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata, and Candida parapsilosis. Murine kinetics showed that Mycograb at 2 mg/kg produced a maximum concentration of drug in serum of 4.7 ug/ml which produced significant improvement in murine candidiasis caused by each species. Complete resolution of infection was achieved for C.albicans, C. krusei, and C. glabrata only after combination with amphotericin B (PMID: 12821470). In a double-blind, randomized study comprising 139 patients it was reported that Mycograb plus lipid-associated amphotericin B produced significant clinical and culture-confirmed improvement in outcome for patients with invasive candidiasis (PMID: 16619152).
English
Deutsch
